Uganda: HIV Prevention - Daily Oral Versus Long-Acting Injectables

Uganda: HIV Prevention - Daily Oral Versus Long-Acting Injectables

[Independent (Kampala)] Shobha Shukla Is the Award-Winning Founding Managing Editor and Executive Director of Cns (Citizen News Service) and Is a Feminist, Health and Development Justice Advocate.

Shobha Shukla: HIV prevention, Daily oral versus long-acting injectables

A lively debate was organised at the recently concluded 10th Asia Pacific AIDS and Co-Infections Conference (APACC 2025) in Tokyo, Japan, on “Should Long-Acting Injectables (LAIs) Replace Oral Antiretrovirals for Biomedical HIV Prevention in the Asia-Pacific Region?” Arguments in favour of long-acting injectable PrEP dwelt upon the current dismally low use of oral PrEP in the Asia Pacific Region – as of end 2023, around 204,000 individuals were …

HIV prevention: Daily oral versus long-acting injectables

Scientific research has gifted us with a range of evidence-based options to protect ourselves from getting infected with HIV. In 2012, the U.S. Food and Drugs Authority (FDA) had first approved Pre-Exposure Prophylaxis (PrEP) daily oral medicines for HIV prevention. More recently, long-acting injectable options of PrEP are also approved. We at Citizen News Service (CNS) listened to the experts on both of these PrEP options so that we can make an…